{"slug":"registry-umin","tag":"registry:umin","variants":["registry:umin"],"description":"No description yet","count":2,"kinds":{"trial":2},"related":[],"records":[{"id":"create-x","kind":"trial","name":"CREATE-X","route":"/trials/create-x/","status":"positive","tldr":"CREATE-X showed that giving the tablet chemotherapy capecitabine for six months after surgery, to women whose breast cancer had not fully disappeared with pre-operative chemotherapy, cut deaths; the gain was largest in triple-negative disease, where five-year survival rose from 70 to 79 percent."},{"id":"ascot-jcog1202","kind":"trial","name":"ASCOT (JCOG1202)","route":"/trials/ascot-jcog1202/","status":"positive","tldr":"In Japan, six months of the oral chemotherapy S-1 after surgery for bile duct, gallbladder or ampullary cancer improved three-year survival from 68 to 77 percent. S-1 is not licensed for this use in the UK or Europe, so the result cannot be applied directly to NHS patients."}]}